Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

Background: Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is often heterogeneous. Weaimed to identify types of disease activity trajectories following the initiation of a new biologic DMARD (bDMARD). Methods: Pooled analysis of nine national registries of patients with diagnosis of RA, who initiated Abatacept and had at least two measures of disease activity (DAS28). We used growth mixture models to identify groups of patients with similar courses of treatment response, and examined these patients' characteristics and effectiveness outcomes. Findings: We identified three types of treatment response trajectories: 'gradual responders' (GR; 3576 patients, 91.7%) had a baseline mean DAS28 of 4.1 and progressive improvement over time; 'rapid responders' (RR; 219 patients, 5.6%) had higher baseline DAS28 and rapid improvement in disease activity; 'inadequate responders' (IR; 103 patients, 2.6%) had high DAS28 at baseline (5.1) and progressive worsening in disease activity. They were similar in baseline characteristics. Drug discontinuation for ineffectiveness was shorter among inadequate responders (p = 0.03), and EULAR good or moderate responses at 1 year was much higher among 'rapid responders' (p < 0.001). Interpretation: Clinical information and baseline clinical characteristics do not allow a reliable prediction of which trajectory the patients will follow after bDMARD initiation. (C) 2016 The Authors. Published by Elsevier B.V.